Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Cost of Capital at DraftKings
Baker, Malcolm P.; Hillenbrand, Sebastian; Barnett, JamesCaso HBS-224007-EFinanzasDesde 8,20 €
-
Behavioral Finance at JP Morgan
Baker, Malcolm P.; Sesia, AldoCaso HBS-207084-EFinanzasFollowing a successful model in Europe, JP Morgan has introduced a set of five U.S. retail mutual funds with an investment philosophy and marketing strategy grounded in behavioral finance. The asset management group believes that understanding investor biDesde 8,20 €
-
Matrix Capital Management (C)
Baker, Malcolm P.; Lane, DavidCaso HBS-211060-EFinanzasBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Desde 5,74 €
-
Restructuring JAL, Teaching Note
Baker, Malcolm P.; Sunderam, AdiNota del Instructor HBS-215041-EFinanzasTeaching note for 214055.Desde 0,00 €
-
Celgene
Baker, Malcolm P.; McComb, Emily R.Caso HBS-218094-EFinanzasIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Desde 8,20 €
-
Restructuring at Nova Chemical Corporation Abridged
Baker, Malcolm P.; Mason, Scott P.Caso HBS-213075-EFinanzasDesde 8,20 €
-
Multifactor Models
Baker, Malcolm P.Caso HBS-207056-EFinanzasStudents evaluate the performance of four mutual funds and compute the cost of capital for two companies using fixed benchmarks, the CAPM, and a multifactor model of returns.Desde 8,20 €
-
Matrix Capital Management (A)
Baker, Malcolm P.; Lane, DavidCaso HBS-211017-EFinanzasBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Desde 8,20 €
-
Celgene (B)
Baker, Malcolm P.; McComb, Emily R.Caso HBS-218099-EFinanzasIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Desde 5,74 €
-
Matrix Capital Management (B)
Baker, Malcolm P.; Lane, DavidCaso HBS-211048-EFinanzasBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Desde 5,74 €